Pediatric GI Opportunities Jaguar Health and its Napo Pharmaceuticals unit are actively presenting crofelemer as adjunctive therapy for pediatric intestinal failure at major gastroenterology meetings, indicating a channel to pediatric hospitals and specialized GI clinics interested in non-opioid, plant-based therapies.

Animal Health Expansion Recent launches and clinical developments for Jaguar Animal Health including Neonorm Dog and crofelemer for chemotherapy-induced diarrhea in dogs create cross-sell potential to veterinary practice groups and pet specialty channels, expanding ASPs and formulary discussions.

Europe Access Focus Jaguar’s minority/majority positioning with Napo Therapeutics in Europe signals a strategic sales path to European distribution partners and health systems seeking plant-derived, non-opioid GI solutions for humans, enabling partnerships and licensing deals.

Natural CNS Pipeline The Magdalena Biosciences joint venture with Filament Health targets natural prescription medicines for mental health and CNS indications, presenting opportunities to license, co-develop, or co-market novel plant-based therapeutics in collaboration with wellness and psychiatric networks.

Clinical Evidence Momentum Ongoing presentations at industry conferences and completed effectiveness studies for crofelemer reinforce evidence to support reimbursement discussions, payer conversations, and formulary inclusion for both human and animal health indications.